Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.Market News: Due to weak sales in the United States, Nissan halved the output of its Mexican factory.Some deposit interest rates have returned to the "2% era". At the end of the year, some small and medium-sized banks "saved money" with high interest rates. Near the end of the year, under the general environment of lowering the RRR and reducing the interest margin, many small and medium-sized banks "bucked the trend", or raised the deposit interest rate and raised interest rates to save money, or launched high-interest deposit products. According to the incomplete statistics of the announcements issued by banks, more than ten small and medium-sized banks have announced to raise deposit interest rates or launch high-interest deposit products. The reporter found out that the phenomenon that some small and medium-sized banks attract customers' deposits at high interest rates does not exist only at the end of the year. In the second half of this year, "high interest rates" are an important "selling point" of their deposit products. (21 Finance)
Some short-term inter-bank bonds performed brilliantly. The yield of 2-year active bonds "21 interest-bearing bonds 02" went down 5bp to reach 1.1%, which was 11bp upside down from the current 1-year active bonds "24 discount bonds 67" yield of 1.21%.It is predicted that the State Council Press Office will hold a press conference at 10 am on Monday, December 16th, 2024, and ask Fu Linghui, spokesperson of the National Bureau of Statistics and head of the National Economic Statistics Department, to introduce the national economic operation in November 2024 and answer questions from reporters.To ensure that patients across the country will use the drugs selected in April next year, the tenth batch of drugs organized by the state will be opened for centralized procurement, and the tenth batch of drugs organized by the state will be selected in Shanghai yesterday, and 62 drugs will be purchased successfully. Covering hypertension, diabetes, tumors, cardiovascular and cerebrovascular diseases, infections, mental diseases and other fields. In the next step, the National Medical Insurance Bureau will guide local and selected enterprises to do a good job in the implementation of the selected results to ensure that patients across the country can use the selected products in this centralized collection in April 2025. (CCTV News)
The launch of Global Development Report 2024 was held in Beijing Foreign Ministry: China is willing to deepen development cooperation with all parties. On the 13th, Foreign Ministry Spokesperson Mao Ning held a regular press conference, and Mao Ning said that the release of Global Development Report is an important measure to implement global development initiatives. This is the third annual report issued by relevant Chinese institutions, aiming at rallying international consensus focusing on development and exploring ideas and cooperation paths to meet global development challenges. As the largest developing country in the world, China is willing to deepen development cooperation with all parties, accelerate the implementation of the United Nations 2030 Agenda for Sustainable Development, and benefit the people of more countries. (CCTV News)Mitsubishi electric will invest $143.5 million to build a heat pump factory in the United States.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.
Strategy guide 12-14
Strategy guide
12-14
Strategy guide